Adaptimmune Therapeutics (ADAP) Reports In-Line Q3 EPS

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q3 EPS of ($0.01), in-line with the analyst estimate of ($0.01). Revenue for the quarter came in at $40.9 million versus the consensus estimate of $18.57 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Alphabet added to Dow Jones Industrial Average, Verizon dropped
• Alfa Laval AB (ALFA:SS) (ALFVY) PT Raised to SEK580 at Deutsche Bank